Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo

NCT06905873 is registered in ClinicalTrials.gov with Forte Biosciences, Inc. as lead sponsor.

NCT NCT06905873
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06905873 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-Segmental Vitiligo
Lead sponsor
Forte Biosciences, Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
March 25, 2025
Completion date
December 31, 2026
Enrollment
64 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo